{"filing":{"accession_number":"0001193125-26-301052","cik":"0001645460","ticker":"CUE","company_name":"Cue Biopharma, Inc.","form":"8-K","filing_date":"2026-07-10","report_date":null,"primary_document":"d123955d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526301052/d123955d8k.htm"},"events":[{"id":17423,"run_id":15599,"accession_number":"0001193125-26-301052","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Cue Biopharma entered into a Securities Purchase Agreement on July 9, 2026, to issue 1,418,071 shares of common stock at $33.21 per share and pre-funded warrants to purchase 87,500 additional shares in a private placement, raising approximately $50.0 million from accredited investors including Cormorant Asset Management and Columbia Threadneedle Investments under Section 4(a)(2) and Rule 506 exemptions.","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-07-10","form":"8-K","submitted_at":null,"items":[{"id":15884,"accession_number":"0001193125-26-301052","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cue Biopharma entered into a Securities Purchase Agreement on July 9, 2026, to issue 1,418,071 shares of common stock at $33.21 per share and pre-funded warrants to purchase 87,500 additional shares, raising approximately $50.0 million in a private placement. This is a classic dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital, fitting the definition of an unregistered sale of equity securities (Item 1.01). The magnitude ($50M) and the involvement of named institutional investors (Cormorant Asset Management, Columbia Threadneedle Investments) make this material to investors assessing the company's capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:18:13.285120+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15885,"accession_number":"0001193125-26-301052","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cue Biopharma announced a $50 million private placement of unregistered equity securities, including 1,418,071 shares of common stock and pre-funded warrants to purchase 87,500 additional shares. The securities are being issued under Section 4(a)(2) and Rule 506 exemptions to accredited investors without SEC registration. This is a classic dilutive equity issuance that materially affects shareholder ownership and is a significant capital-raising event for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:18:13.285120+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15887,"accession_number":"0001193125-26-301052","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a $50.0 million private placement of common stock and pre-funded warrants by Cue Biopharma to accredited investors, with 1,418,071 shares at $33.21 per share and 87,500 pre-funded warrants at $33.209 per warrant. This is a classic dilutive equity issuance under Item 8.01 (Other Events), material to investors as it significantly increases share count and dilutes existing shareholders. The company explicitly notes the securities are unregistered and subject to a registration rights agreement for future resale.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:18:13.285120+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":17424,"run_id":15599,"accession_number":"0001193125-26-301052","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The Board granted restricted stock units (RSUs) to executive officers (Shao-Lee Lin, Sumita Ray, Michael Meluzio) and non-employee directors on July 9, 2026, pursuant to the 2026 Stock Incentive Plan approved at the most recent shareholder meeting.","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-07-10","form":"8-K","submitted_at":null,"items":[{"id":15886,"accession_number":"0001193125-26-301052","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The Item 5.02 disclosure centers on the Board's grant of RSUs to executive officers (Shao-Lee Lin, Sumita Ray, Michael Meluzio) and non-employee directors on July 9, 2026, pursuant to the 2026 Stock Incentive Plan approved at the most recent shareholder meeting. This is a compensatory arrangement disclosure under Item 5.02(e), not a departure or appointment. The supplemental exhibit regarding the $50M private placement is contextual but does not alter the primary event disclosed in Item 5.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:18:13.285120+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15884,"accession_number":"0001193125-26-301052","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cue Biopharma entered into a Securities Purchase Agreement on July 9, 2026, to issue 1,418,071 shares of common stock at $33.21 per share and pre-funded warrants to purchase 87,500 additional shares, raising approximately $50.0 million in a private placement. This is a classic dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital, fitting the definition of an unregistered sale of equity securities (Item 1.01). The magnitude ($50M) and the involvement of named institutional investors (Cormorant Asset Management, Columbia Threadneedle Investments) make this material to investors assessing the company's capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:18:13.285120+00:00","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-07-10"},{"id":15885,"accession_number":"0001193125-26-301052","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cue Biopharma announced a $50 million private placement of unregistered equity securities, including 1,418,071 shares of common stock and pre-funded warrants to purchase 87,500 additional shares. The securities are being issued under Section 4(a)(2) and Rule 506 exemptions to accredited investors without SEC registration. This is a classic dilutive equity issuance that materially affects shareholder ownership and is a significant capital-raising event for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:18:13.285120+00:00","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-07-10"},{"id":15886,"accession_number":"0001193125-26-301052","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The Item 5.02 disclosure centers on the Board's grant of RSUs to executive officers (Shao-Lee Lin, Sumita Ray, Michael Meluzio) and non-employee directors on July 9, 2026, pursuant to the 2026 Stock Incentive Plan approved at the most recent shareholder meeting. This is a compensatory arrangement disclosure under Item 5.02(e), not a departure or appointment. The supplemental exhibit regarding the $50M private placement is contextual but does not alter the primary event disclosed in Item 5.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:18:13.285120+00:00","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-07-10"},{"id":15887,"accession_number":"0001193125-26-301052","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a $50.0 million private placement of common stock and pre-funded warrants by Cue Biopharma to accredited investors, with 1,418,071 shares at $33.21 per share and 87,500 pre-funded warrants at $33.209 per warrant. This is a classic dilutive equity issuance under Item 8.01 (Other Events), material to investors as it significantly increases share count and dilutes existing shareholders. The company explicitly notes the securities are unregistered and subject to a registration rights agreement for future resale.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:18:13.285120+00:00","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-07-10"}]}